The Bacterial Antibiotics Pipeline: Still Broken, No Fix in Sight

I’ve been heads down working on the new startup recently, but had to pause at the news that J&J is exiting the bacterial antibiotics space. They’ll still develop antivirals (targeting HIV, flu, and the common cold) and vaccines (including one against ExPEC, extraintestinal pathogenic E. coli), but it looks like they’re winding down efforts againstContinue reading “The Bacterial Antibiotics Pipeline: Still Broken, No Fix in Sight”